• 1
    Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:127581.
  • 2
    von Minckwitz G, M. Kaufmann SK, Fasching PA, et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol 2011;29.
  • 3
    Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:201927.
  • 4
    von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:55262.
  • 5
    von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:54251.
  • 6
    von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19:2928.
  • 7
    von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005;16:5663.
  • 8
    von Minckwitz G BJ, Costa S, Denkert C, et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients—results of the GeparTrio Trial. Oral presentation at the 34rd San Antonio Breast Cancer Symposium, San Antonio, TX, December 6–10, 2011.
  • 9
    Loibl S GvM, Blohmer JU, Costa SD, et al. pCR as a surrogate in HER2-positive patients treated with trastuzumab. Cancer Res (Abstracts: Thirty-Fourth Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 6–10, 2011) 2012;71:S5S4.
  • 10
    Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011;29:195662.
  • 11
    Schneeweiss A, Schuetz F, Rudlowski C, et al. Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. Anticancer Drugs 2005;16:10238.
  • 12
    Schneeweiss A, Huober J, Sinn HP, et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. Eur J Cancer 2004;40:24328.
  • 13
    Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:173647.
  • 14
    Untch M, Mobus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009;27:293845.
  • 15
    Untch M, Fasching PA, Konecny GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel {+/−} darbepoetin α in primary breast cancer—results at the time of surgery. Ann Oncol 2011.
  • 16
    Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010;28:287480.
  • 17
    Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14319.
  • 18
    Kummel S, Krocker J, Kohls A, et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 2006;94:123744.
  • 19
    Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:77885.
  • 20
    Yerushalmi R, Woods R, Ravdin PM, et al. Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:17483.
  • 21
    Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki-67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst 2011.